Effect of embelin on TRAIL receptor 2 mab-induced apoptosis of TRAIL-resistant a549 non-small cell lung cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 10, 2013, Pages 6115-6120

  Jiang, Lei ^a   Hao, Jin Li ^a   Jin, Mu Lan ^a   Zhang, Yun Gang ^a   Wei, Ping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Embelin; Lung cancer; TRAIL

Indexed keywords

BENZOQUINONE DERIVATIVE; CASPASE; EMBELIN; MONOCLONAL ANTIBODY; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84890483189     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.10.6115     Document Type: Article

References (29)

1. Cheng YJ, Jiang HS, Hsu SL, et al (2010). XIAP-mediated protection of H460 lung cancer cells against cisplatin. Eur J Pharmacol, 627, 75-84.
2. Chitra M, Sukumar E, Suja V, Devi CS (1994). Antitumor, antiinflammatory and analgesic property of embelin, a plant product. Chemotherapy, 40, 109-13.
3. Chou TC (2008). Preclinical versus clinical drug combination studies. Leuk Lymphoma, 49, 2059-80.
4. Cooper WA, Kohonen-Corish MR, Zhuang L, et al (2008). Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmallcell lung cancer and precursor lesions. Cancer, 113, 135-42.
5. Dai Y, Qiao L, Chan KW, et al (2009). Peroxisome proliferatoractivated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. Cancer Res, 69, 4776-83.
6. De Petris L, Crino L, Scagliotti GV, et al (2006). Treatment of advanced non-small cell lung cancer. Ann Oncol, 17, ii36-41.
7. Duiker EW, Mom CH, de Jong S, et al (2006). The clinical trail of TRAIL. Eur J Cancer, 42, 2233-40.
8. Fesik SW (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer, 5, 876-85.
9. Field JK, Duffy SW (2008). Lung cancer screening: the way forward. Br J Cancer, 99, 557-62.
10. Gross A, McDonnell JM, Korsmeyer SJ (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev, 13, 1899-911.
11. Holcik M, Gibson H, Korneluk RG (2001). XIAP: apoptotic brake and promising therapeutic target. Apoptosis, 6, 253-61.
12. Ihde DC, Minna JD (1991). Non-small cell lung cancer. Part II: Treatment. Curr Probl Cancer, 15, 105-54.
13. Jo M, Kim TH, Seol DW, et al (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med, 6, 564-7.
14. Kaminskyy VO, Surova OV, Piskunova T, et al (2013). Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling. Cell Death Dis, 4, e522.
15. Kim K, Fisher MJ, Xu SQ, el-Deiry WS (2000). Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res, 6, 335-46.
16. Koschny R, Ganten TM, Sykora J, et al (2007). TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 45, 649-58.
17. Lan Y, Liu X, Zhang R, et al (2013). Lithium enhances TRAILinduced apoptosis in human lung carcinoma A549 cells. Biometals, 26, 241-54.
18. Li XQ, Ke XZ, Wang YM (2012). Treatment of malignant melanoma by downregulation of XIAP and overexpression of TRAIL with a conditionally replicating oncolytic adenovirus. Asian Pac J Cancer Prev, 13, 1471-6.
19. Luster TA, Carrell JA, McCormick K, et al (2009). Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther, 8, 292-302.
20. Mahalingam D, Szegezdi E, Keane M, et al (2009). TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev, 35, 280-8.
21. Mori T, Doi R, Kida A, et al (2007). Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res, 142, 281-6.
22. Nikolovska-Coleska Z, Xu L, Hu Z, et al (2004). Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem, 47, 2430-40.
23. Pore MM, Hiltermann TJ, Kruyt FA (2010). Targeting apoptosis pathways in lung cancer. Cancer Lett, 332, 359-68.
24. Siegelin MD, Gaiser T, Siegelin Y (2009). The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int, 55, 423-30.
25. Spierings DC, de Vries EG, Timens W, et al (2003). Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res, 9, 3397-405.
26. Sprick MR, Weigand MA, Rieser E, et al (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12, 599-609.
27. Stegehuis JH, de Wilt LH, de Vries EG, et al (2009). TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat, 13, 2-15.
28. Voortman J, Resende TP, Abou El Hassan MA, et al (2007). TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther, 6, 2103-12.
29. Zhang L, Fang B (2005). Mechanisms of resistance to TRAILinduced apoptosis in cancer. Cancer Gene Ther, 12, 228-37.